@article{ATM25540,
author = {Raphaële Charest-Morin and Charles G. Fisher and Ann L. Versteeg and Arjun Sahgal and Peter Pal Varga and Daniel M. Sciubba and James M. Schuster and Michael H. Weber and Michelle J. Clarke and Laurence D. Rhines and Stefano Boriani and Chetan Bettegowda and Michael G. Fehlings and Paul M. Arnold and Ziya L. Gokaslan and Nicolas Dea},
title = {Clinical presentation, management and outcomes of sacral metastases: a multicenter, retrospective cohort study},
journal = {Annals of Translational Medicine},
volume = {7},
number = {10},
year = {2019},
keywords = {},
abstract = {Background: Sacral metastases are rare and literature regarding their management is sparse. This multicenter, prospective, observational study aimed to determine health related-quality of life (HRQOL) and pain in patients treated for sacral metastases with surgery and/or radiation therapy (RT). The secondary objectives were to describe the adverse event (AE) profile and change in neurologic function in this population.
Methods: Twenty-three patients presenting with symptomatic sacral metastases were identified from the Epidemiology, Process and Outcomes of Spine Oncology (EPOSO) dataset, a prospective multicenter study on spinal metastases. Patients requiring surgery and/or RT between August 2013 and February 2017 were prospectively enrolled. HRQOL, assessed by the Spine Oncology Study Group Outcomes Questionnaire (SOSGOQv2.0), the Short Form-36 version 2 (SF-36v2), and the EuroQol-5Dimension (EQ-5D) was documented at baseline, 6 weeks, 3 and 6 months post-treatment. Pain numeric rating scale (NRS), AEs, lower extremities motor score (ASIA), and bowel and bladder function were also recorded.
Results: Eight patients underwent surgery ± RT and 15 patients underwent RT alone. Mean age was 59.3 (SD 11.7) years and 13 patients were female. At 6 months, 3 (37.5%) surgical patients and 2 (13.3%) RT patients were deceased. There was a trend showing that surgical patients had worse baseline HRQOL and pain. Pain NRS, EQ-5D, SOSGOQv2.0, and the mental component of the SF-36v2 showed improvement, irrespective of treatment (P>0.05). Ten AEs occurred in the surgical cohort, dominated by wound complications (n=3). Bowel and bladder function improved at 6 weeks in both groups.
Conclusions: Surgical treatment and RT are both valid treatment options for symptomatic sacral metastases. Improvement in HRQOL can be expected with an acceptable AE rate.},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/25540}
}